Coagulation and morbidity in treated HIV infection

Area of Science:

• Cardiovascular Medicine
• Infectious Diseases
• Hematology

Background:

• HIV infection is linked to increased venous and arterial thromboembolic events.
• Elevated inflammation markers (IL-6, TNFrI, CRP) and coagulation factors (tissue factor, FVIII, thrombin, fibrinogen, D-dimer) are observed in HIV patients.
• Chronic immune activation and inflammation in HIV may drive abnormal coagulation.

Purpose of the Study:

• To explore the mechanisms behind heightened thrombotic risk in HIV infection.
• To investigate the role of inflammation and coagulation markers in predicting outcomes for HIV patients.
• To consider the impact of traditional risk factors like smoking and dyslipidemia in HIV-associated thrombosis.

Main Methods:

• Review of existing literature on inflammation, coagulation, and thrombosis in HIV.
• Analysis of data from interventional studies targeting inflammation and cardiovascular risk in HIV.
• Assessment of predictive value of various biomarkers for thrombotic events and mortality.

Main Results:

• Multiple inflammation and coagulation markers are significantly increased in HIV infection.
• Several of these markers are predictive of thrombotic risk and mortality in HIV disease.
• Chronic inflammation and immune activation are implicated in the pathogenesis of coagulopathy.

Conclusions:

• HIV patients exhibit an elevated risk of thromboembolic events, driven by inflammatory and coagulation abnormalities.
• Traditional risk factors, prevalent in the HIV population, exacerbate this thrombotic risk.
• Further research and interventions targeting inflammation are crucial for managing cardiovascular risk in HIV.